Distribution Notice

Distribution Notice
22 May 2023


Section 1: Issuer information
Name of issuer AFT Pharmaceuticals Limited (“AFT”)
Financial product name/description Final Dividend
NZX ticker code AFT
ISIN (If unknown, check on NZX
website)
NZAFTE0001S4
Type of distribution
(Please mark with an X in the
relevant box/es)
Full Year X Quarterly
Half Year Special
DRP applies
Record date 19/06/2023
Ex-Date (one business day before the
Record Date)
16/06/2023
Payment date (and allotment date for
DRP)
04/07/2023
Total monies associated with the
distribution
$1,153,529
Source of distribution Retained earnings and Income available for distribution
Currency NZD
Section 2: Distribution amounts per financial product
Gross distribution
1
$0.01100000
Gross taxable amount
2
$0.01100000
Total cash distribution
3
$0.01100000
Excluded amount (applicable to listed
PIEs)
N/A
Supplementary distribution amount N/A
Section 3: Imputation credits and Resident Withholding Tax
4

Is the distribution imputed No imputation
If fully or partially imputed, please
state imputation rate as % applied
N/A

1
“Gross distribution” is the total cash distribution plus the amount of imputation credits, per financial product, before the deduction of
Resident Withholding Tax (RWT).
2
“Gross taxable amount” is the gross distribution minus any excluded income.
3
“Total cash distribution” is the cash distribution excluding imputation credits, per financial product, before the deduction of RWT.
This should include any excluded amounts, where applicable to listed PIEs.
4
The imputation credits plus the RWT amount is 33% of the gross taxable amount for the purposes of this form. If the distribution is
fully imputed the imputation credits will be 28% of the gross taxable amount with remaining 5% being RWT. This does not constitute
advice as to whether or not RWT needs to be withheld.

Imputation tax credits per financial
product
N/A
Resident Withholding Tax per
financial product
$0.00363000
Section 4: Distribution re-investment plan (if applicable)
Not applicable

Section 5: Authority for this announcement
Name of person

authorised to make
this announcement
Malcolm Tubby
Contact person for this
announcement
Malcolm Tubby
Contact phone number +64 9 242 1230
Contact email address malcolm@aftpharm.com
Date of release through MAP

22/05/2023